Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic is a brand-name injectable medication containing semaglutide, a GLP-1 receptor agonist approved by the FDA in 2017 for managing type 2 diabetes. While the drug carries a diabetes indication, emerging clinical evidence has documented significant changes in body weight among patients using it for glucose control. PlexusDx provides access to compounded semaglutide therapy tailored to individual metabolic profiles.

Understanding Ozempic's Original FDA Indication and Mechanism

Ozempic received its primary FDA approval for type 2 diabetes management, not weight management. The medication works by binding to GLP-1 receptors in the pancreas, brain, and gut, which stimulates insulin secretion when blood sugar rises and slows gastric emptying. These mechanisms help regulate blood glucose levels in people with diabetes. Semaglutide's action on appetite centers in the hypothalamus and its effects on satiety hormones create secondary metabolic changes that many patients experience.

Clinical trials supporting Ozempic's diabetes indication revealed an unexpected finding: participants lost an average of 3 to 6 pounds during the two-year SUSTAIN program. This observation prompted separate research into semaglutide's use for weight management in non-diabetic populations. The STEP trials (2021) specifically examined semaglutide's effects on body weight in people without diabetes, showing sustained reductions of 15 to 22 percent over 68 weeks. These findings created clinical interest in semaglutide's potential beyond its original diabetes indication.

How Semaglutide Affects Weight When Used for Metabolic Health

Semaglutide influences weight through multiple biological pathways that extend beyond simple appetite suppression. The medication activates GLP-1 receptors throughout the central and peripheral nervous systems, which reduces hunger signals, increases feelings of fullness, and slows the rate at which food moves from the stomach into the small intestine. These combined effects naturally lead to reduced calorie intake without requiring restrictive dieting. Additionally, semaglutide may increase resting metabolic rate and improve insulin sensitivity, which can facilitate weight loss independent of dietary changes alone.

The drug's effects on appetite-regulating hormones like cholecystokinin and peptide YY create sustained metabolic adjustments rather than temporary appetite loss. Patients typically report feeling satisfied with smaller meal portions and experiencing fewer food cravings. These neurological changes tend to persist as long as the medication is used, making it a maintenance tool rather than a short-term intervention. Research indicates that most weight loss occurs within the first 6 to 12 months of consistent therapy, with stabilization thereafter.

The Difference Between Ozempic Use and Compounded Semaglutide Therapy

Ozempic is a brand-name product manufactured by Novo Nordisk and prescribed off-label for weight management, meaning healthcare providers use it for an indication outside its FDA-approved diabetes label. Compounded semaglutide, by contrast, is a customized version prepared by licensed 503A compounding pharmacies according to individual prescriptions and specifications. Both contain the same active pharmaceutical ingredient, but compounding allows for personalized dose titration, flexible scheduling, and cost structures tailored to individual needs. PlexusDx sources semaglutide from licensed 503A compounding pharmacies exclusively, ensuring pharmaceutical-grade quality without membership requirements or insurance dependency.

Compounded semaglutide typically costs less than brand-name Ozempic, which can exceed $900 per month before insurance or manufacturer programs. PlexusDx offers compounded semaglutide injections starting at $149 per month, with your dose able to increase as needed while your price remains flat. The compounding approach also enables practitioners to adjust formulations based on individual tolerance, contraindications, and metabolic response. Patients access treatment across all 50 states with HSA and FSA eligibility, removing geographic and financial barriers that often limit Ozempic access.

Genetic Insights and Personalized Semaglutide Optimization

Individual responses to semaglutide vary considerably based on genetic architecture affecting appetite regulation and metabolic pathways. PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway genetic assessment that examines key variants such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These genetic markers influence how effectively a person's body responds to GLP-1 receptor signaling, how hunger signals are processed, and baseline metabolic rates. Mapping these 49 peptides across 14 distinct pathways provides 150+ actionable genetic insights that guide therapy personalization.

Patients with specific GLP1R or GIPR variants may experience stronger appetite suppression and more rapid weight loss, while those with particular FTO or MC4R variants may benefit from longer dose ramp-up periods or combination therapies. The Precision Peptide Genetic Test ($99 add-on after first month of treatment) identifies these individual predispositions, allowing practitioners to optimize semaglutide dosing, predict response timelines, and determine whether dual-peptide protocols like GLP-Squared might offer additional benefits. This precision approach transforms weight management from trial-and-error experimentation into data-driven, personalized medicine.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic actually approved by the FDA for weight loss?

No. Ozempic received FDA approval specifically for type 2 diabetes management in 2017. Healthcare providers may prescribe it off-label for weight management based on clinical evidence, but this use falls outside the medication's official indication. PlexusDx provides access to compounded semaglutide, which practitioners can prescribe for metabolic health optimization.

How much weight can someone lose using semaglutide?

Clinical trials show average weight loss ranges from 10 to 22 percent of body weight over 68 weeks, depending on dose and individual response. Results vary significantly based on genetic factors, baseline metabolic rate, and adherence to treatment. PlexusDx's Precision Peptide Genetic Test identifies individual predispositions that help predict likely response and optimize dosing for maximum effectiveness.

What makes PlexusDx semaglutide different from Ozempic?

PlexusDx offers compounded semaglutide from licensed 503A pharmacies at a flat rate starting at $149/month, with no insurance required and HSA/FSA eligibility. Your dose can increase while your price stays the same. Access spans all 50 states, and optional genetic testing helps personalize therapy for faster, more predictable results.

Are there safety concerns with compounded semaglutide?

Compounded semaglutide from licensed 503A pharmacies meets rigorous pharmaceutical standards for purity and potency. Common side effects mirror those of brand-name semaglutide and typically include mild nausea, which often resolves with dose adjustment. Contraindications include personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2; patients should discuss full medical history with their provider.

How does the Precision Peptide Genetic Test help with semaglutide therapy?

The test examines genetic variants in GLP-1 and GLP-IR pathways, appetite-control genes (MC4R, FTO), and related metabolic pathways. Results reveal individual predispositions to GLP-1 responsiveness, baseline metabolic rates, and whether dual-peptide protocols might provide additional benefits. At $99, it personalizes therapy and helps practitioners predict response timelines and optimize dosing strategy.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves